VIR as reported
Vir Biotechnology, Inc. reported $69M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.
$69M
Revenue, trailing twelve months · to Q4 2025 · every figure below is as filed, with no scoring applied
- Net Income
- −$443M
Net Income · −23% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$450M
Free Cash Flow · +6.5% year on year · trailing twelve months to Q1 2026
- Op Margin
- −21675%
Op Margin · trailing twelve months to Q4 2025
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $69M | n/a | Q4 2025 |
| Net Income | −$443M | −23% | Q1 2026 |
| EPS | −$3.12 | −26% | Q1 2026 |
| Gross Margin | 98% | n/a | Q2 2025 |
| Op Margin | −21675% | n/a | Q4 2025 |
| Net Margin | −20293% | n/a | Q4 2025 |
| ROE | −58% | n/a | Q1 2026 |
| ROA | −45% | n/a | Q1 2026 |
| Free Cash Flow | −$450M | +6.5% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Vir Biotechnology, Inc. (VIR) - Revenue & ProfitRevenue & ProfitVir Biotechnology, Inc. (VIR)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com